Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“The Future of Cancer Treatment is Here – But Are We Ready?
I’m thrilled to discuss a groundbreaking shift in oncology that could change everything we know about cancer treatment.
Free Webinar Registration Link.
Tissue-agnostic cancer therapies – treatments that target molecular drivers regardless of where the tumor originated – are no longer just a promising concept. They’re a clinical reality with incredible potential.
The numbers speak volumes:
- A real-world study of nearly 300,000 tumors revealed that 21.5% have tissue-agnostic indications
- We now have 9 FDA-approved tissue-agnostic therapies
Yet significant implementation challenges remain in translating this promise to patient care.
What’s holding us back? I’m excited to dive deep into this topic during the upcoming Caris Life Sciences webinar series, where we’ll explore George Sledge’s pivotal research ‘Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals’ and my editorial commentary ‘Tissue-agnostic cancer therapies: promise, reality, and the path forward’ – both published in Nature Communications.
This isn’t just about new drugs – it’s about fundamentally reimagining how we approach cancer treatment. The potential to help patients based on their tumor’s molecular fingerprint, not just its location, represents one of the most significant advances in modern oncology.
Join the conversation – what do you see as the biggest barriers to implementing precision medicine in your practice or institution?
More posts featuring Vivek Subbiah.
